The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 146 participants.

Also called NCT07897409

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 146 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07897409
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07897409. Randomized; no masking; primary purpose prevention. Start 2026-12-01 (anticipated); primary completion 2027-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity
Acronym
NICBREASTRCT
Condition
Doxorubicin Induced Cardiotoxicity
Condition
Doxorubicin Induced Cardiomyopathy
Condition
Doxorubicin
Condition
Doxorubicin Adverse Reaction
Intervention (Drug)
Nicorandil Oral Tablet
Intervention (Drug)
Adriamycin (Doxorubicin)
Lead sponsor
Universiti Sains Malaysia (class: other)

Record details

Record id
cardio:ct-nct07897409
Content hash
cf34a73b5aa2cc94eb9e1b098438e41f85db580e2d0942e0120e889761e499b6